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Abstract
The midbrain periaqueductal gray (PAG), and its descending projections to the
rostral ventromedial medulla (RVM), provides an essential neural circuit for opioidproduced antinociception. Recent anatomical studies have reported that the projections
from the PAG to the RVM are sexually dimorphic and that systemic administration of
morphine significantly suppresses pain-induced activation of the PAG in male but not
female rats. Given that morphine antinociception is produced in part by disinhibition of
PAG output neurons, it is hypothesized that a differential activation of PAG output
neurons mediates the sexually dimorphic actions of morphine. The present study
examined systemic morphine-induced activation of PAG-RVM neurons in the absence
of pain. The retrograde tracer fluorogold (FG) was injected into the RVM to label PAGRVM output neurons. Activation of PAG neurons was determined by quantifying the
number of Fos-positive neurons one hour following systemic morphine administration
(4.5 mg/kg). Morphine produced comparable activation of the PAG in both male and
female rats, with no significant differences in either the quantitative or qualitative
distribution of Fos. While microinjection of FG into the RVM labeled significantly more
PAG output neurons in female rats than male rats, very few of these neurons (20%)
were activated by systemic morphine administration in comparison to males (50%). The
absolute number of PAG-RVM neurons activated by morphine was also greater in
males. These data demonstrate widespread disinhibition of PAG neurons following
morphine administration. The greater morphine-induced activation of PAG output
neurons in male compared to female rats is consistent with the greater morphineinduced antinociception observed in males.
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Morphine and other mu-opioid receptor agonists are the most effective
pharmacological treatment for the alleviation of persistent pain. However, it is becoming
increasingly clear that morphine does not produce the same degree of analgesia in
males and females. In the majority of studies reported to date, morphine produced a
greater antinociceptive response in males in comparison to females (Bodnar et al.,
1988, Craft, 2003b, Craft, 2003a, Cook and Nickerson, 2005, Wang et al., 2006). Sex
differences in morphine analgesia have been reported in studies employing orofacial
(Okamoto et al., 2005), somatic (Bartok and Craft, 1997, Cicero et al., 1997, Boyer et
al., 1998, Kest et al., 1999, Barrett et al., 2001) or visceral (Ji et al., 2006, Ji et al., in
press) pain models. To date, the mechanism(s) whereby morphine produces a
differential degree of analgesia is unknown.
The midbrain periaqueductal gray (PAG), and its descending projections to the
rostral ventromedial medulla (RVM) and spinal cord, comprises an essential neural
circuit for both endogenous and exogenous opioid-mediated analgesia (Basbaum et al.,
1978, Basbaum and Fields, 1978, Basbaum and Fields, 1984). The PAG contains a
high density of mu opioid receptors (Commons et al., 1999, Commons et al., 2000,
Wang and Wessendorf, 2002) and microinjection of opioid antagonists into the PAG
significantly attenuates systemic morphine-produced analgesia (Zambotti et al., 1982,
Randich et al., 1992, Lane et al., 2005, Bernal et al., 2007). Similarly, microinjection of
the mu opioid selective neurotoxin dermorphin-saporin (Porreca et al., 2001, Burgess et
al., 2002, Vera-Portocarrero et al., 2006a, Vera-Portocarrero et al., 2006b) into the PAG
significantly attenuates systemic morphine analgesia (Loyd and Murphy, 2007).
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Together, these studies indicate that the PAG is a primary neural structure for opioidmediated analgesia.
Recent studies have reported sex differences in both the anatomical and
physiological organization of the PAG-RVM pathway. These sex differences may
provide the biological bases for the observed sexually dimorphic actions of morphine.
For example, recent anatomical studies have shown that females have a significantly
greater number of PAG neurons retrogradely labeled from the RVM in comparison to
males. Interestingly, persistent inflammatory pain only activates this pathway in males.
Similarly, systemic morphine administration decreases noxious stimulus-induced
activation of the PAG in male but not female rats (Loyd and Murphy, 2006). Together,
these studies suggest a sexually dimorphic action of morphine within the PAG. This
suggestion is further supported by studies showing that microinjection of morphine into
the PAG produces greater antinociception in male in comparison to female rats
(Krzanowska and Bodnar, 1999, Bernal et al., 2007, Wang et al., submitted).
Electrophysiological studies have reported that morphine, as well as other opioid
agonists, inhibit and excite different populations of PAG neurons. In vitro recordings
have shown that opioids disinhibit PAG-RVM output neurons by presynaptically
inhibiting tonically active GABAergic neurons (Behbehani et al., 1990a, Behbehani et
al., 1990b, Chieng and Christie, 1994, Stiller et al., 1995). This GABA-mediated
disinhibition results in the activation of PAG-RVM neurons. However, other studies have
shown that opioids directly inhibit a subset of PAG-RVM projection neurons (Chieng and
Christie, 1994, Osborne et al., 1996), and mu opioid receptors have been localized on
approximately 27-50% of PAG neurons retrogradely labeled from the RVM (Commons
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et al., 2000, Wang and Wessendorf, 2002). If GABA disinhibition is the primary
mechanism for morphine action in the PAG, then administration of morphine should
preferentially induce Fos in PAG-RVM output neurons. By contrast, if morphine
antinociception is primarily mediated via direct inhibition of PAG-RVM output neurons,
then systemic administration of morphine should not induce Fos in these neurons as
induction Fos induction requires membrane depolarization (Greenberg et al., 1986a,
Greenberg et al., 1986b, Bartel et al., 1989).
The present studies were conducted to determine whether morphine administration
preferentially activates PAG-RVM output neurons using retrograde tract tracing in
combination with Fos immunocytochemistry. Morphine-induced Fos in PAG-RVM output
neurons was compared in male and females rats to determine if there were qualitative
or quantitative sex differences in activation of this pathway. If sex differences in the
PAG-RVM circuit provide that bases for the sexually dimorphic actions of morphine,
then activation of this pathway should be greater in male compared to female rats.

1. Experimental Procedures
1.1. Subjects
Adult male and weight-matched (250-350g) cycling female Sprague-Dawley rats
(Zivic-Miller; Pittsburg, PA) were used. Rats were housed in same-sex pairs in separate
rooms on a 12:12 hour light: dark cycle (lights on at 7:00A.M.). Access to food and water
was ad libitum throughout the experiment except during surgery. Vaginal lavages were
taken daily to determine if the female rats were cycling normally and to keep daily
records on the stages of their cycle in respect to the experimental testing. These
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studies were performed in compliance with the Institutional Animal Care and Use
Committee at Georgia State University.
1.2. Retrograde Tracer Injections
Six male and six female rats were deeply anesthetized with ketamine/xylazine
(50 mg/kg / 10mg/kg; s.c.) and placed in a stereotaxic frame. The position of the skull
was adjusted so that bregma and lambda were at the same dorsal-ventral plane. Glass
micropipettes (10-20 µM) filled with the retrograde tracer Fluorogold (FG; 2% soln. w/v
in saline; Fluorochrome LLC; Denver, CO) were lowered into the RVM using the
following coordinates (in mm): AP: -2.0 Lambda; ML: 0.0; DV: -8.5. FG was
iontophoresed (50/50 duty cycle, 7.5 µA current) into the RVM for 25 minutes to
facilitate neuronal uptake. The current was then turned off, and the pipettes remained
in place for an additional 5 minutes to reduce backflow of tracer along the pipette track.
Only males and females that had comparable injection sites were used for data
collection. Following tracer injections, wounds were sutured closed, the antibiotic
Neosporin was applied to the wound, and the animals were placed in clean cages to
recover under a heat lamp. Upon complete recovery from the anesthetic, animals were
returned to their original housing facilities.
1.3. Morphine Administration
All animals were given a subcutaneous injection of either morphine sulfate (4.5
mg/kg, s.c.; NIDA; Bethesda, MD) or sterile saline as a control. All injections were
performed between the hours of 12:00P.M. and 2:00P.M. Morphine sulfate was prepared
fresh in a saline vehicle within one hour prior to injection.
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1.4. Perfusion fixation
One hour after morphine administration, animals were given a lethal dose of
Nembutal (160 mg/kg; i.p.). The animals were transcardially perfused with 150-200 ml
of 0.9% sodium chloride containing 2% sodium nitrite as a vasodilator, to remove blood
from the brain. Immediately following removal of blood, 300 ml of 4% paraformaldehyde
in 0.1M phosphate buffer containing 2.5% acrolein (Polyscience; Niles, IL) was perfused
through the brain as a fixative. A final rinse with 150-200 ml of the sodium
chloride/sodium nitrate solution was perfused through the brain to remove any residual
acrolein. Immediately following perfusion, the brains were carefully removed, placed in
a 30% sucrose solution and stored at 40C for at least one week prior to sectioning. To
section the brain, the dura and pia matter were carefully removed and the brains were
cut into six series of 25 µm coronal sections with a Leica 2000R freezing microtome and
stored free-floating in cryoprotectant-antifreeze solution (Watson et al., 1986) at –20oC
until immunocytochemical processing.
1.5. Immunocytochemistry
A 1:6 series through the rostrocaudal axis of each brain was processed for FG
and/or Fos immunoreactivity as previously described (Murphy and Hoffman, 2001).
Briefly, sections were rinsed extensively in potassium phosphate-buffered saline
(KPBS) to remove cryoprotectant solution immediately followed by a 20-minute
incubation in 1% sodium borohydride to remove excess aldehydes. The tissue was
then incubated in primary antibody solution(s) previously described (Loyd and Murphy,
2006): rabbit anti-Fos (Oncogene; Cambridge, MA, lot no. 4194; 1:50,000) and/or rabbit
anti-FG (Chemicon; Billerica, MA, lot no. 25060005; 1:10,000) in KPBS containing 1.0%
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Triton-X for one hour at room temperature followed by 48 hours at 4°C. After rinsing out
the primary antibody with KPBS, the tissue was incubated for one hour in biotinylated
goat anti-rabbit IgG (Jackson Immunoresearch; West Grove, PA, 1:200), rinsed with
KPBS, followed by a one hour incubation in an avidin-biotin peroxidase complex (1:10;
ABC Elite Kit, Vector Labs). After rinsing in KPBS and sodium acetate (0.175 M; pH
6.5), Fos was visualized as a black reaction product using nickel sulfate intensified 3,3’diaminobenzidine solution containing 0.08% hydrogen peroxide in sodium acetate
buffer. FG was visualized as a brown reaction product using 3,3’-diaminobenzidine
containing 0.08% hydrogen peroxide in Trizma buffer (pH 7.2). After 15-30 minutes,
three rinses in sodium acetate buffer terminated the reaction. Sections were then
mounted out of saline onto gelatin-subbed slides, air-dried overnight, dehydrated in a
series of graded alcohols, cleared in xylene, and cover-slipped using Permount.
1.6. Data Analysis and Presentation
The number of PAG-RVM output neurons (FG+), the number of activated intrinsic
PAG neurons (Fos+), and the number of activated PAG-RVM output neurons (Fos+FG)
was determined across six rostrocaudal levels of PAG (Bregma -6.72, -7.04, -7.74, 8.00, -8.30, -8.80). Neurons were counted in two PAG subdivisions: dorsomedial and
lateral/ventrolateral; these subdivisions are clearly distinguishable based on the
distribution of retrograde labeling from the RVM (van Bockstaele et al., 1991, Bandler
and Shipley, 1994). The lateral/ventrolateral region was counted unilaterally as there
are no differences in the number of FG+ cells for the left versus right side of PAG (Loyd
and Murphy, 2006). There are no cytoarchitectural or anatomical boundaries between
the lateral and ventrolateral regions; therefore, these regions were counted together to
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avoid experimenter bias. The tissue was sectioned at 25 µm so that 125 µm separates
each analyzed level of the PAG thus avoiding any bias of counting the same cell twice.
Additionally, previous data has shown that there are no sex differences in the mean
area (mm2) of PAG between weight-matched male and female Sprague-Dawley rats
(Loyd and Murphy, 2006).
Data are expressed as the mean + standard error of the mean (SEM) from which
percentages were calculated. A four-way analysis of variance (ANOVA) was used to
test for significant main effects of sex (male, female), PAG subdivision (dorsomedial,
lateral/ventrolateral), PAG level (Bregma –6.72 through -8.80) and treatment (morphine,
saline). P<0.05 was considered significant for all analyses. For data presentation, a
representative animal from each experimental group was selected and the distribution
of FG and Fos within the PAG were plotted using a Nikon Drawing Tube attached to a
Nikon Optiphot microscope. Plots were then scanned onto the computer and adjusted to
figure format using Adobe Illustrator 10. Photomicrographs were generated using a
Synsys digital camera attached to a Nikon Eclipse E800 microscope. Images were
captured with IP Spectrum software, adjusted to figure format by adjusting brightness
and contrast levels using Adobe Photoshop 7.0.

2. Results
2.1. Systemic Morphine-Induced Activation of the PAG
The objective of the present experiment was to examine if morphine activation of
the PAG is quantitatively and/or qualitatively different in male and female rats. Animals
were given a systemic injection of either morphine (4.5 mg/kg, s.c.; n=6/sex) or sterile
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saline (n=5 males and n=6 females) and perfused one hour later. The distribution and
number of neurons expressing Fos were determined across six rostrocaudal levels of
the PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, -8.80) and within the dorsomedial
and lateral/ventrolateral regions.
In animals treated with systemic morphine, Fos+ cells were primarily distributed
throughout the dorsomedial, lateral and ventrolateral regions of the PAG with very little
Fos in the dorsolateral or ventromedial regions (see Figure 1). The quantity and
distribution of Fos labeled neurons was relatively consistent across the rostrocaudal
axis of the PAG (Bregma –6.72 to –8.80 mm) and was almost two-fold greater in
morphine treated animals in comparison to saline control [F(1,252) = 106.7, p < 0.0001].
In animals treated with morphine, the mean number of Fos+ cells in the rostral PAG was
77.5 + 13.4 in comparison to 25 + 8 in saline treated animals. Caudally (Bregma -8.30),
the mean number of Fos+ cells in morphine treated animals was 78 + 3 versus 33 + 7
for saline control. Morphine administration induced comparable Fos expression in the
PAG in both male and female rats [F (1,252) = 1.60, p > 0.05]. For example, at rostral
levels of PAG (Bregma -7.04), the mean number of Fos+ cells was 73 + 16 for males, in
comparison to 77 + 13 for females. More caudally (Bregma -8.30), the mean number of
Fos+ cells was 78.3 + 14 in males in comparison to 81 + 12 in females.
2.2. Sexually Dimorphic Activation of the PAG-RVM Circuit by Morphine
The results from the first set of experiments demonstrate that acute morphine
administration induces greater activation of the PAG compared to acute saline
administration, and that this activation is comparable in male and female rats. The
objectives of the next experiment were to determine (1) whether morphine preferentially
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activates PAG-RVM output neurons, and (2) if this activation is sexually dimorphic.
Animals received Fluorogold injections into the RVM; ten days later they were injected
with either systemic morphine (4.5 mg/kg; n=5 per sex) or sterile saline (n=5 males and
n=6 females) and perfused one hour later.
Figure 2 shows an example of a typical iontophoretic injection of FG into the
RVM of a male (top) and female (bottom). All injections were located on the midline and
dorsal to the pyramidal tract, at the level of the caudal pole of the facial nucleus (lambda
–2.0mm). Injections outside of the RVM were not included for analysis.
Injection of FG into the RVM produced dense retrograde labeling across the
rostrocaudal axis of the PAG in both male and female rats. As reported previously
(Loyd & Murphy, 2006), there were significantly more retrogradely labeled neurons
across all rostrocaudal levels of the PAG in female as compared to male rats [F (1,216)
= 48.2, p < 0.0001]. Acute systemic administration of morphine induced Fos labeling in
a subset of PAG output neurons in both male and female rats. The number of activated
PAG output neurons was consistently higher in the PAG of male compared to female
rats (Figure 3). An example of morphine induced Fos within FG+ cells is shown in
Figure 4. At rostral levels of PAG (Bregma -6.72), the mean number of double-labeled
cells in the lateral/ventrolateral subdivision of the PAG was 18 + 4 for males, in
comparison to 6 + 1 for females. More caudally (Bregma -8.30), the mean number of
double-labeled cells in the lateral/ventrolateral subdivision of the PAG was 42 + 11 in
males, in comparison to 20 + 3 in females. This activation of output neurons was
significantly greater in male compared to female rats whether analyzed as number of
double labeled neurons [F(1,192) = 43.3, p < 0.0001] (Figure 3), percent of FG labeled
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neurons expressing Fos [F(1,192) = 223.2, p < 0.0001] or percent Fos that was
expressed in FG neurons [F(1,192) = 65.379, p < 0.0001] (Figure 5). The greater mean
number of Fos-positive PAG-RVM neurons in male rats is particularly noteworthy given
that the total number of projecting neurons is greater in female rats. The greater number
of double labeled neurons in male rats is evident in both dorsomedial and
lateral/ventrolateral regions across all rostrocaudal levels of the PAG (Figure 3).
The number of double-labeled cells also varied across PAG levels with caudal
regions showing greater label in the lateral/ventrolateral compared to dorsomedial
subdivision and rostral regions showing comparable labeling in the two subdivisions. An
ANOVA on the number of Fos+ neurons revealed a significant main effect of levels-bysubdivision interaction [F(5,252) = 2.97, p < 0.05]; no other interactions reached
significance (p > 0.05).

3. Discussion
It is becoming increasingly evident that morphine produces a greater degree of
analgesia in males in comparison to females. To date, the mechanisms underlying sex
differences in morphine analgesia remain unknown. The PAG and its descending
projections to the RVM provide the primary circuit for opioid-produced analgesia, and
sex differences in the activation of this circuit by morphine would be predicted to
contribute to the reported sex differences in morphine analgesia. The results of our
studies demonstrate that systemic morphine administration induces extensive Fos
expression within the PAG of male and female rats. Interestingly, while no sex
differences were noted in the overall number or distribution of morphine-induced Fos,
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morphine preferentially activated the PAG-RVM circuit in males. Indeed, at most rostralcaudal levels of PAG, the percentage of PAG-RVM neurons expressing morphine
induced Fos was two-fold higher in males in comparison to females.
In the present study, the observed morphine-induced Fos may be due to direct
actions of morphine at the mu opioid receptor (MOR) or alternatively, due to secondary
effects associated with morphine administration, including changes in blood pressure,
respiration and cardiac output. These autonomic changes have been shown previously
to induce Fos expression within the PAG of the rat (Murphy et al., 1995). However, as
pharmacological or neurotoxic blockade of MOR in the PAG significantly attenuates the
analgesic effects of systemic morphine, this suggests that the Fos observed in the
present study was primarily due to direct actions of morphine in the PAG. In support,
Fos expression was primarily localized within the dorsomedial and lateral/ventrolateral
PAG; these regions contain high levels of mu opioid receptor (Commons et al., 2000,
Wang and Wessendorf, 2002, Wang et al., submitted). Interestingly, mu opioid
receptors are virtually absent in the dorsolateral PAG; similarly, this region contained
very little, if any, morphine-induced Fos.

3.1. The PAG-RVM Circuit is Preferentially Activated in Male Rats
Fluorogold injection into the RVM produced dense retrograde labeling within the
dorsomedial, lateral and ventrolateral divisions of the PAG, consistent with previous
anatomical studies in the rat (Beitz et al., 1983, van Bockstaele et al., 1991, Rizvi et al.,
1996). Interestingly, while the number of PAG neurons retrogradely labeled from the
RVM is almost two-fold higher in females in comparison to males, very few of these
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PAG-RVM cells were activated by morphine (FG/Fos; overall between 14-25% of FG+
cells). Similarly, although morphine induced comparable levels of Fos within the PAG of
males and females, the percentage of Fos present in FG+ cells (Fos/FG) was only
between 14-25%. By contrast, in males, the percentage of FG+ cells co-expressing Fos
ranged between 48-77%, while the percentage of Fos+ cells labeled with FG was
between 34-54%. The results of the present study indicating that between 48-77% of
PAG-RVM neurons in males express morphine induced Fos suggest that administration
of morphine results primarily in the net excitation of PAG-RVM neurons, most likely
through removal of tonic GABA inhibition (Moreau and Fields, 1986, Behbehani et al.,
1990b, Vaughan and Christie, 1997, Commons et al., 2000). Direct inhibition of PAGRVM neurons by morphine may also contribute to morphine analgesia and cannot be
ruled out in the present study.
Interestingly, while females had extensive Fos present in the PAG, very little Fos
was present in PAG output neurons. As activation of the PAG-RVM pathway is essential
for morphine-induced analgesia, these results provide a likely mechanism for sex
differences in morphine analgesia. It is not clear why females had such extensive Fos
expression overall in the PAG, but very little in RVM projection neurons. Unfortunately,
to date, no in vitro recordings have been conducted from female PAG slices so the
effects of morphine on the physiological properties of PAG neurons can only be inferred
from male data. Clearly, this needs to be addressed in the future. One possibility is that
in females, morphine activates a pain facilitation network. A PAG-RVM pain facilitatory
system has been shown to contribute to hyperalgesia produced by opiate withdrawal
(Bederson et al., 1990), chronic inflammation (Terayama et al., 2000, Guan et al.,
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2002), and morphine tolerance (Vanderah et al., 2001). Interestingly, morphine-induced
hyperalgesia is significantly more pronounced in females in comparison to males
(Holtman and Wala, 2005).
Alternatively, there may be a sex difference in the organization or function of the
GABAergic system inhibiting the PAG cells involved in modulating nociceptive
transmission. Intra-PAG administration of GABA antagonists block pain behaviors
(Budai and Fields, 1998; Moreau and Fields, 1986) and lead to depolarization,
increased firing frequency, and increased excitatory post-synaptic potentials in PAG
neurons responsive to GABA (Behbehani et al., 1990b). Intra-PAG GABA agonists
(Moreau and Fields, 1986) and mu opioid receptor antagonists (Budai and Fields, 1998)
reverse the analgesic effects of the GABA antagonists and of morphine. While the
ventrolateral PAG contains a high density of mu opioid receptors, very few of the
neurons that project to the RVM are directly inhibited by opioid agonists (Osborne et al.,
1996). In the present study, males had greater activation of the PAG-RVM pathway by
systemic morphine, suggesting that morphine is acting through local GABA neurons
(Bellchambers et al., 1998), whereas females potentially have a different organization or
function of this GABAergic system.
The present study used gonadally intact, cycling females and a number of
studies have suggested that gonadal steroids may influence morphine potency. For
example, treatment of female rat pups with androgen on the day of birth results in a
leftward shift of the morphine dose response curve (Krzanowska and Bodnar, 1999,
Cicero et al., 2002, Cataldo et al., 2005). In adulthood, ovariectomy increases morphine
potency in female rats and this effect is blocked by exogenous estradiol replacement
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(Negus and Mello, 1999, Stoffel et al., 2005, Ji et al., in press). Similarly, in males,
castration decreases and testosterone replacement restores morphine potency (Stoffel
et al., 2005). The rat PAG contains a dense population of estrogen (ERα) and androgen
(AR) receptor containing neurons (Murphy and Hoffman, 1999, Murphy and Hoffman,
2001, Marson and Murphy, 2006). These receptors are localized in similar regions of
the PAG as the mu opioid receptor and in our preliminary studies, we noted that a large
proportion of PAG-RVM neurons also contain ERα. In hypothalamic slices, estrogen
has been shown to rapidly uncouple the mu opioid receptor from G protein-gated
inwardly rectifying potassium channels resulting in a reduced hyperpolarization by MOR
agonists (Kelly et al., 2003). Estrogen-mediated hyperpolarization of PAG-RVM
neurons would provide a direct mechanism whereby morphine failed to elicit Fos in
PAG-RVM neurons. Alternatively, as the gene encoding Fos contains an estrogen
response element (Loose-Mitchell et al., 1988, Wang et al., 2003), changes in cycle
status may have potentially influenced the ability of morphine to induce Fos in PAGRVM neurons in females. Lastly, estradiol has also been shown to induce MOR
internalization (Eckersell et al., 1998, Sinchak and Micevych, 2001, Micevych et al.,
2003, Mills et al., 2004); this would limit the amount of receptor available for ligand
binding and would thereby potentially decrease morphine’s ability to induce Fos in PAGRVM neurons. Future studies are necessary to further test these potential mechanisms.
3.2. Sexually Dimorphic PAG-RVM Pathway
The results of the present study indicate that morphine preferentially activates
the PAG-RVM pathway in males. These results concur with our previous study
demonstrating that persistent inflammatory pain selectively activates the PAG-RVM

16

pathway in males, but not females. In that study, we also demonstrated that morphine
preferentially suppressed persistent pain induced Fos in males, but not females.
Unfortunately, the effects of morphine on persistent pain induced Fos in PAG-RVM
output neurons was quite variable, and it was unknown whether the effects we were
observing were due to morphine acting directly on PAG-RVM neurons and/or if
morphine was decreasing pain-induced drive to the PAG. In the present study,
morphine was given in the absence of pain and was shown to preferentially activate the
PAG-RVM circuit in males. Indeed, at most rostral-caudal levels of the PAG, the
percentage of PAG-RVM neurons expressing morphine induced Fos was two-fold
higher in males in comparison to females. As the PAG-RVM circuit is essential for
morphine analgesia, sex differences in the activation of this pathway may provide the
biological bases for the sexually dimorphic actions of morphine.
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Figure Legends
Figure 1. Distribution of morphine-induced Fos in male and female rats at six
rostrocaudal levels of the PAG. Each black circle represents one Fos-immunoreactive
cell. Bar graphs compare the mean number (+ S.E.M.) of Fos-immunoreactive cells in
male and female rats 1 hr after administration of morphine or saline. Morphine
administration induced a significant increase in the number of Fos labeled neurons
compared to saline. This increase was comparable in male and female rats.
Figure 2. Representative examples of FG injection into the RVM of a male (top) and
female (bottom) rat. All injections were along the midline and in the bottom third of the
medulla. Gi, gigantocellularis; 7, facial nucleus; py, pyramidal tract; 4V, fourth ventricle.
Figure 3: Distribution of PAG-RVM output neurons that expressed morphine-induced
Fos in male and female rats across six rostrocaudal levels of the PAG. Each black
circle represents one double-labeled (Fos+FG) cell. Bar graphs display the mean
number of Fos+FG cells (+ S.E.M.) for each level of the dorsomedial and
lateral/ventrolateral regions of the PAG. Fos labeling was greater in male than female
rats in all PAG regions measured.
Figure 4: Photomicrograph showing morphine-induced Fos in FG+ cells for males (A,
10X; B, 20X) and females (C, 10X; D, 20X). Note that while females have a greater
number of FG+ cells than males, very few of these cells expressed morphine-induced
Fos (indicated with red arrows). No sex differences were noted in the total number of
Fos+ cells.
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Figure 5: Percentage of morphine-induced Fos+ PAG neurons that were retrogradely
labeled from the RVM (Fos+FG) in male (left) and female (right) rats in the dorsomedial
and lateral/ventrolateral regions of the PAG at six representative levels. The proportion
of Fos positive neurons projecting to the RVM was greater in male than female rats
across all PAG regions.
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